Summary of clinical trials of ibrutinib in this analysis
| Protocol . | Trial identification number . | Regimen . | Total number of patients enrolled . | Number of patients who discontinued ibrutinib . |
|---|---|---|---|---|
| 2010-0314 | NCT01105247 | Ibrutinib (RR-CLL) | 41 | 15 |
| 2011-0785 | NCT01520519 | Ibrutinib + rituximab (high-risk CLL) | 40 | 15 |
| 2012-0707 | NCT01578707 | Ibrutinib vs ofatumumab (RR-CLL) | 17 | 2 |
| 2012-0086 | NCT01752426 | Ibrutinib/heavy water | 29 | 1 |
| Total | 127 | 33 |
| Protocol . | Trial identification number . | Regimen . | Total number of patients enrolled . | Number of patients who discontinued ibrutinib . |
|---|---|---|---|---|
| 2010-0314 | NCT01105247 | Ibrutinib (RR-CLL) | 41 | 15 |
| 2011-0785 | NCT01520519 | Ibrutinib + rituximab (high-risk CLL) | 40 | 15 |
| 2012-0707 | NCT01578707 | Ibrutinib vs ofatumumab (RR-CLL) | 17 | 2 |
| 2012-0086 | NCT01752426 | Ibrutinib/heavy water | 29 | 1 |
| Total | 127 | 33 |